Therapeutic potential of Crispr/Cas-9 gene edited apolipoprotein B-null cells and insulin signalling in lipoprotein metabolism

^*Corresponding author for this work

Research output: Contribution to journal › Meeting abstract › peer-review

5 Citations (Scopus)

Original language	English
Pages (from-to)	S413-S414
Number of pages	2
Journal	Diabetologia
Volume	65
DOIs	https://doi.org/10.1007/s00125-022-05755-w
Publication status	Published - 03 Aug 2022
Event	58th Annual Meeting of the European Association for the Study of Diabetes - Stockholm, Sweden Duration: 19 Sept 2022 → 23 Sept 2022 https://www.easd.org/annual-meeting/easd-2022.html

Access to Document

@article{18817e55e10c4616bd2c362190e8460e,

title = "Therapeutic potential of Crispr/Cas-9 gene edited apolipoprotein B-null cells and insulin signalling in lipoprotein metabolism",

author = "Q. Su and H. Wade",

year = "2022",

month = aug,

day = "3",

doi = "10.1007/s00125-022-05755-w",

language = "English",

volume = "65",

pages = "S413--S414",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer Science and Business Media Deutschland GmbH",

note = "58th Annual Meeting of the European Association for the Study of Diabetes, EASD ; Conference date: 19-09-2022 Through 23-09-2022",

url = "https://www.easd.org/annual-meeting/easd-2022.html",

}

TY - JOUR

T1 - Therapeutic potential of Crispr/Cas-9 gene edited apolipoprotein B-null cells and insulin signalling in lipoprotein metabolism

AU - Su, Q.

AU - Wade, H.

PY - 2022/8/3

Y1 - 2022/8/3

U2 - 10.1007/s00125-022-05755-w

DO - 10.1007/s00125-022-05755-w

M3 - Meeting abstract

SN - 0012-186X

VL - 65

SP - S413-S414

JO - Diabetologia

JF - Diabetologia

T2 - 58th Annual Meeting of the European Association for the Study of Diabetes

Y2 - 19 September 2022 through 23 September 2022

ER -